Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Aberrant PI3K/AKT signaling is a hallmark of acute B-lymphoblastic leukemia (B-ALL) resulting in increased tumor cell proliferation and apoptosis deficiency. While previous AKT inhibitors struggled with selectivity, MK-2206 promises meticulous pan-AKT targeting with proven anti-tumor activity. We he...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Anna, Fischer, Elisabeth, Holz, Clemens, Schulze, Julia, Lange, Sandra, Sekora, Anett, Knuebel, Gudrun, Henze, Larissa, Roolf, Catrin, Escobar, Hugo Murua, Junghanss, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967241/
https://www.ncbi.nlm.nih.gov/pubmed/33803402
http://dx.doi.org/10.3390/ijms22052771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967241/
https://www.ncbi.nlm.nih.gov/pubmed/33803402
http://dx.doi.org/10.3390/ijms22052771

Ejemplares similares